| Description | SB 204990 is an effective and specific ATP citrate lyase enzyme inhibitor. |
| In vitro | SB204990 treatment leads to a reduction in cytosolic Ac-CoA level and is thus expected to decrease acetylated and active β-catenin levels [1]. |
| In vivo | SB 204990 is absorbed into the systemic circulation when administered orally to rats. SB 204990 causes a dose-related decrease in plasma cholesterol (by up to 46%) and triglyceride levels (by up to 80%) in rats when administered in the diet (0.05-0.25%, w/w) for 1 week. SB 204990 (25 mg/kg per day) also decreases plasma cholesterol levels (by up to 23%) and triglyceride levels (by up to 38%) in the dog, preferentially decreasing low-density lipoprotein compared with high-density lipoprotein cholesterol levels [2]. |
| molecular weight | 389.27 |
| Molecular formula | C18H22Cl2O5 |
| CAS | 154566-12-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 100 mg/mL (256.89 mM) H2O: 10 mg/mL (25.69 mM), Sonication is recommended. |
| References | 1. Shares BH, et al. Active mitochondria support osteogenic differentiation by stimulating β-catenin acetylation. J Biol Chem. 2018 Oct 12;293(41):16019-16027. 2. Pearce NJ, et al. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem J. 1998 Aug 15;334 ( Pt 1):113-9. |